BioVie Inc., also known as BIVI, has revealed the details of its latest public offering. It's a robust endeavor, comprising of 21 million shares of common stock and inclusive of warrants to buy up to an additional 10.5 million shares of common stock. These will all be offered at a combined price of $1.00 per share and warrant each. Furthermore, the exercise price for these warrants is set at $1.50 per share.
From this venture, BioVie Inc. anticipates grossing roughly around $21 million. The primary use of these net proceeds has been outlined as supplementing working capital and bolstering general corporate purposes. The closing of this offering is predicted to be executed by March 6, 2024.
